Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.

摘要: The endocannabinoid system was discovered in 1988 but has received little attention for its potential therapeutic possibilities. That started to change, and since 2000, a significant number of clinical trials cannabinoids, principally the control spasticity multiple sclerosis, have been undertaken. These studies difficult because nature disease involved patients whom other therapies failed or proved inadequate. This paper outlines background use cannabinoids available discusses principles practice associated with their safe use. focus on nabiximols, being most studied only cannabinoid that both adequately researched sclerosis granted license by regulators. However, what emerged is effect many can be much wider than just spasticity. Within outside neurology there seems an expanding range possibilities cannabinoids.